— Published Date: 7/7/2026
Value Proposition: This invention introduces a mucosal vaccine that can provide immunity against multiple Sarbecoviruses.
Technology Description
Researchers at Washington University in St. Louis have developed an adenoviral-vectored vaccine that can induce broad immunity…
— Published date: 5/20/2026
Value Proposition: Potential adjunctive therapy for E. coli pyelonephritis to mitigate the renal tissue damage associated with infection, thereby reducing renal scarring and other long-term complications of renal scarring.
Technology Description
Researchers at Washingt…
— Published date: 1/14/2026
Value Proposition: Method and composition to potently neutralize EEEV infection.
Technology Description
Researchers at Washington University in St. Louis have developed very low-density lipoprotein receptor (VLDLR) soluble decoy receptors with potent inhibitory acti…
— Published date: 1/14/2026
Value Proposition: Fusion protein that can be used to prevent and treat arthritogenic alphavirus infections.
Technology Description
Researchers at Washington University in St. Louis have identified MXRA8 (matrix remodeling associated protein 8) protein as a key recepto…
— Published date: 1/14/2026
Value Proposition: Decoy receptor therapeutic that can treat multiple VEEV subtypes by blocking VEEV entry and infection.
Technology Description
Researchers at Washington University in St. Louis have developed a decoy Ldlrad3-D1-Fc protein for prevention of treatment o…
— Published date: 1/14/2026
Value Proposition: Entry receptors that bind directly to TBEV, promoting virus attachment to treat TBEV and other viruses.
Technology Description
Researchers at Washington University in St. Louis have developed LRP8 soluble decoy receptors (minimal domains-Fc fusion …
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
